Status:
COMPLETED
Comparison Of Efficacy and Safety Between Ticagrelor and Clopidogrel In Chinese
Lead Sponsor:
Tongji Hospital
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This is a prospective, single-center study to assess the long- and short-term outcomes of ticagrelor vs clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary in...
Eligibility Criteria
Inclusion
- 18 years of age or older;
- diagnosed as acute coronary syndrome;
- underwent successful percutaneous coronary intervention.
Exclusion
- participate in any drug clinical trials within 3 months;
- patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years;
- serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients);
- previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix);
- patients refused to comply with the requirements of this study to complete the research work.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 24 2021
Estimated Enrollment :
9040 Patients enrolled
Trial Details
Trial ID
NCT03239067
Start Date
August 1 2014
End Date
October 24 2021
Last Update
November 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital
Wuhan, Hubei, China, 430030